Tests whether lab-grown tumor tissue predicts osteosarcoma chemotherapy response
Studies whether lab-grown tumor cultures from biopsies can predict osteosarcoma response to chemotherapy.
Key facts
- Who runs it
- Jonsson Comprehensive Cancer Center
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- An Organoid-based Functional Precision Medicine Trial in Osteosarcoma
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 12 Feb 2024
- Expected to end
- 1 Jan 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- standard of care biopsy
- Record updated
- 11 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people whose scans suggest osteosarcoma (a bone cancer) and who are already planned to have a biopsy or surgery to confirm the diagnosis.
- Sex
- All sexes can join.
- Disease stage
- Group 1: scans suggest osteosarcoma, not yet diagnosed. Group 2: scans suggest osteosarcoma that has spread (metastatic).
The registry criteria, word for word
Show all 3 criteriaShow less
Other criteria
- Inclusion / exclusion criteria - Group1:
- Patients without diagnosis of osteosarcoma and whose imaging studies are suggestive of osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes; Inclusion / exclusion criteria - Group 2:
- Patients whose imaging studies are suggestive of metastatic osteosarcoma and who are planned to undergo biopsy or surgery for diagnostic purposes
Where in United States
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles, United StatesContact: Summer SwearingenTaking people
About the trial
What the trial wants to find out
The purpose of this study is to examine if we can predict sensitivity of osteosarcoma to different chemotherapy agents using tissue cultures in the laboratory. We know that different chemotherapy agents can be used in the treatment, but not every sarcoma responds to them equally. It is important to understand if testing of the tissue obtained during a routine biopsy or surgery may be useful in selecting appropriate treatments. In addition, additional testing of the tumor, including genetic testing, will help us to understand osteosarcoma better.
The 2 groups in the trial
- Group 1: local tumor
patients with localized osteosarcoma who are scheduled to undergo diagnostic biopsy and are planned for surgical excision of the primary tumor
Treatment: standard of care biopsy
- Group 2: metastatic disease
patients with metastatic osteosarcoma who are scheduled to undergo either biopsy or surgery of metastatic disease
Treatment: standard of care biopsy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Organoid-based Functional Precision Medicine Trial in Osteosarcoma: PREMOST
- Plain-language title
- Tests whether lab-grown tumor tissue predicts osteosarcoma chemotherapy responseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 May 2026